IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Maurice Winn who wrote (1588)	7/13/1998 9:32:00 AM
From: Bob L	Read Replies (1) of 1762

Which part makes you ill? The last sentence? If so, I just felt I should add a disclaimer, as I have been accused of bias in favor of IDPH and CLTR. But any preliminary results from trials can go sour when others try to replicate it with different or more subjects. You know this as well as I, of course. There is the risk that the small sample so far is biased, perhaps unwittingly, towards lymphoma cell types that rituxan is more effective against. Personally, I think idph has a good shot at serious competition in aggressive lymphomas. Oncologists aren't going to be so concerned about a few nasty side effects. They are used to mixing and matching worse combinations. But I don't want nervous tcln folks mad at me for saying so. Half of the aggressive lymphoma market is infinitely bigger than the current market share, and with the stock so low, things can still be rosy for tcln just from oncolym. But interesting that cltr has not done anything with a chemo combination, at least yet. I'm just stumbling around in the dark on this topic, like the rest of us.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next